Biotech
-
Avidia
New protein structural motifs for treating human disease.
Acquired by Amgen (AMGN) -
Calithera Biosciences
A new class of anti-cancer therapeutics based on activation of caspases
(CALA) -
Catalyst Biosciences
Developer of engineered proteases as protein therapeutics that attack targets which cause disease.
PRIVATE -
Elcelyx Therapeutics
Elcelyx is a biotechnology company that is creating new therapeutics for the treatment of diabetes and obesity
-
FoldRx Pharmaceuticals
Treatments for diseases caused by misfolding of specific proteins
Acquired by Pfizer -
Morphotek, Inc.
Next generation antibodies production technology.
Acquired by EISIA -
Mosaic Biosciences
Platform for tissue engineering using synthetic smart polymers
-
OncoMed Pharmaceuticals Inc.
Biological therapeutics targeting cancer stem cells
(OMED) -
Orexigen
Developer of drug treatments for obesity and related disorders.
(OREX) -
Principia
Drug discovery company based on a proprietary chemistry platform that generates novel compounds with enhanced selectivity, high potency and longer duration of effect
-
Promedior Pharmaceuticals
Therapeutics to treat fibrosis
PRIVATE -
Ra Pharmaceuticals
Platform for orally available and cell permeable biologics
(RARX) -
Replidyne
Drug discovery and development focused on a new class of antibiotics
(RDYN) -
Ribozyme Pharmaceuticals
RNA-based pharmaceuticals for human disease
(RZYM) -
Scioderm
Scioderm is focused on the development of innovative drugs for the treatment of chronic diseases of the skin.
Acquired by Amicus
-
Stemgent
Reagents for stem cell researchers
PRIVATE -
Threshold Pharmaceutical, Inc.
Developing targeted therapies for treatment of cancer.
(THLD) -
Tragara Pharmaceuticals
Developer of drugs for the treatment of cancer and inflammation-related diseases.
PRIVATE -
Trellis Bioscience
Platform technology for monoclonal antibody development and production
PRIVATE -
Vapotherm
Vapotherm is developing high flow therapy for clinically effective respiratory support.
-
Vical
DNA-based pharmaceuticals for human disease
(VICL)